Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Apr 4:365:l1141.
doi: 10.1136/bmj.l1141.

Medicinal use of cannabis based products and cannabinoids

Tom P Freeman  1   2   3   4 , Chandni Hindocha  3   4   5 , Sebastian F Green  4 , Michael A P Bloomfield  3   4   5   6   7
Affiliations

Medicinal use of cannabis based products and cannabinoids

Tom P Freeman et al. BMJ. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interestsThe BMJ has judged that there are no disqualifying financial ties to commercial companies. The authors declare the following other interests: TPF was funded by a senior academic fellowship from the Society for the Study of Addiction (SSA). MAPB is funded by a UCL Excellence Fellowship. MAPB, SFG, and CH are supported by the National Institute for Health Research (NIHR) University College London Hospitals Biomedical Research Centre. The views expressed here are those of the authors, and do not reflect those of the SSA, the University of Bath, UCL, or NIHR. The funders had no role on the planning, researching, or writing of this report or in the decision to submit it for publication. Further details of The BMJ policy on financial interests is here: https://www.bmj.com/about-bmj/resources-authors/forms-policies-and-checklists/declaration-competing-interests

Figures

Fig 1
Fig 1
Non medicinal CBD products are widely available
See this image and copyright information in PMC

References

    1. The Misuse of Drugs (Amendments) (Cannabis and Licence Fees) (England, Wales and Scotland) Regulations 2018 http://www.legislation.gov.uk/uksi/2018/1055/pdfs/uksi_20181055_en.pdf
    1. Pavlovic R, Nenna G, Calvi L, et al. Quality traits of “cannabidiol oils”: cannabinoids content, terpene fingerprint and oxidation stability of European commercially available preparations. Molecules 2018;23:1230. 10.3390/molecules23051230 - DOI - PMC - PubMed
    1. Niesink RJ, Rigter S, Koeter MW, Brunt TM. Potency trends of Δ9-tetrahydrocannabinol, cannabidiol and cannabinol in cannabis in the Netherlands: 2005-15. Addiction 2015;110:1941-50. 10.1111/add.13082 - DOI - PubMed
    1. Kalk NJ, Boyd A, Strang J, Finch E. Spice and all things nasty: the challenge of synthetic cannabinoids. BMJ 2016;355:i5639. 10.1136/bmj.i5639 - DOI - PubMed
    1. Schoedel KA, Szeto I, Setnik B, et al. Abuse potential assessment of cannabidiol (CBD) in recreational polydrug users: A randomized, double-blind, controlled trial. Epilepsy Behav 2018;88:162-71. 10.1016/j.yebeh.2018.07.027 - DOI - PubMed

MeSH terms